Do we really know who has an MGMT methylated glioma?: results of an international survey regarding use of MGMT analyses for glioma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Winther Kristensen Bjarne) > Do we really know w...

Details
MARC

Malmström, Annika,1957-Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Närvårdskliniken (author)

Do we really know who has an MGMT methylated glioma? : results of an international survey regarding use of MGMT analyses for glioma

Article/chapterEnglish2020

Publisher, publication year, extent ...

2019-09-24
Oxford :Oxford University Press,2020
electronicrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-169110
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-169110URI
https://doi.org/10.1093/nop/npz039DOI
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-160808URI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background: Glioma O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status informs clinical decision making. Worldwide different methods and cutoff levels are used, which can lead to discordant methylation results.Methods: We conducted an international survey to clarify which methods are regularly used and why. We also explored opinions regarding international consensus on methods and cutoff.Results: The survey had 152 respondents from 25 countries. MGMT methylation status is determined for all glioblastomas in 37% of laboratories. The most common methods are methylation-specific polymerase chain reaction (msPCR) (37%) and pyrosequencing (34%). A method is selected for simplicity (56%), cost-effectiveness (50%), and reproducibility of results (52%). For sequencing, the number of CpG sites analyzed varies from 1–3 up to more than 16. For 50% of laboratories, the company producing the kit determines which CpG sites are examined, whereas 33% select the sites themselves. Selection of cutoff is equally distributed among a cutoff defined in the literature, by the local laboratory, or by the outside laboratory performing the analysis. This cutoff varies, reported from 1% to 30%, and in 1 laboratory tumor is determined as methylated in case of 1 methylated CpG site of 17 analyzed. Some report tumors as unmethylated or weakly vs highly methylated. An international consensus on MGMT methylation method and cutoff is warranted by 66% and 76% of respondents, respectively. The method preferred would be msPCR (45%) or pyrosequencing (42%), whereas 18% suggest next-generation sequencing.Conclusion: Although analysis of MGMT methylation status is routine, there is controversy regarding laboratory methods and cutoff level. Most respondents favor development of international consensus guidelines.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
LANTBRUKSVETENSKAPER Veterinärmedicin Medicinsk biovetenskap hsv//swe
AGRICULTURAL SCIENCES Veterinary Science Medical Bioscience hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Klinisk laboratoriemedicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Clinical Laboratory Medicine hsv//eng
glioma
international consensus guidelines
international survey
laboratory methods and cutoff level
MGMT testing

Added entries (persons, corporate bodies, meetings, titles ...)

Lysiak, Malgorzata,1989-Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten(Swepub:liu)mally72 (author)
Kristensen, Bjarne WintherDepartment of Pathology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Denmark (author)
Hovey, ElizabethDepartment of Medical Oncology, Nelune Comprehensive Cancer Centre, Prince of Wales Hospital , Randwick, Sydney, NSW, Australia University of New South Wales , Sydney, Australia (author)
Henriksson, RogerUmeå universitet,Onkologi,Department of Radiation Sciences, University of Umeå , Sweden(Swepub:umu)rohe0003 (author)
Söderkvist, Peter,1953-Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten(Swepub:liu)petso43 (author)
Linköpings universitetAvdelningen för cellbiologi (creator_code:org_t)

Related titles

In:Neuro-Oncology PracticeOxford : Oxford University Press7:1, s. 68-762054-25772054-2585

Internet link

Find in a library

Neuro-Oncology Practice (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Malmström, Annik ...; Lysiak, Malgorza ...; Kristensen, Bjar ...; Hovey, Elizabeth; Henriksson, Roge ...; Söderkvist, Pete ...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

AGRICULTURAL SCIENCES: AGRICULTURAL SCI ...; and Veterinary Scien ...; and Medical Bioscien ...

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Clinical Laborat ...

Articles in the publication: Neuro-Oncology P ...

By the university: Umeå University; Linköping University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se